Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rate (bCRR) after TAFA-LEN were 13.5% and 7.7%, respectively. Outcomes were better for patients who relapsed >6 months after CAR T-cell therapy (mPFS2: 5.6 vs 2 months, P = .0138; mOS2: not reached vs 3.8 months, P = .0034). The bORR and bCRR between TAFA-LEN and other treatments were 20.6% vs 24.9% and 11.6% vs 15.6%, respectively. Outcomes were similar between TAFA-LEN and other treatments (mPFS2: 2.9 vs 2.4 months, P = .91; mOS2: 3.3 vs 5.5 months, P = .06). In an exploratory analysis of the TL-pre-CAR-T set, the median TAFA-LEN treatment duration before CAR-T was 3.7 months with no patient becoming CD19 negative. The bORR, bCRR, 6- month PFS, and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1%, and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatment improved outcomes for patients relapsing after CAR T-cell therapy.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2024-10-11
DOI
https://doi.org/10.1182/bloodadvances.2024013726
Citations
12
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
3.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Jérôme Paillassa, Gabriel Brisou, Lucie Obéric, Sébastien Bailly et al.
12 citations
Blood Advances
CAR-T cell therapy research
3.39
article

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Jérôme Paillassa, Gabriel Brisou, Lucie Obéric, Sébastien Bailly, Sylvain Choquet, Steven Le Gouill, Luc‐Matthieu Fornecker, Adrien Chauchet, Roch Houot, François Lemonnier, Cristina Castilla‐Llorente, Alexandra Marquet, Charles Herbaux, Franck Morschhauser, Arnaud Campidelli, Daphné Krzisch, Olivier Casasnovas, Gandhi Laurent Damaj, Olivier Hermine, Krimo Bouabdallah, Vincent Camus, Pierre Sesques, Sylvain Carras, Benoît Tessoulin, Fabrice Jardin, Stéphanie Guidez, Justine Decroocq, Ledraa Tounes, Julie Abraham, Laurianne Drieu La Rochelle, Magalie Joris, Vivien Dupont
article en
12 citations

Abstract

Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rate (bCRR) after TAFA-LEN were 13.5% and 7.7%, respectively. Outcomes were better for patients who relapsed >6 months after CAR T-cell therapy (mPFS2: 5.6 vs 2 months, P = .0138; mOS2: not reached vs 3.8 months, P = .0034). The bORR and bCRR between TAFA-LEN and other treatments were 20.6% vs 24.9% and 11.6% vs 15.6%, respectively. Outcomes were similar between TAFA-LEN and other treatments (mPFS2: 2.9 vs 2.4 months, P = .91; mOS2: 3.3 vs 5.5 months, P = .06). In an exploratory analysis of the TL-pre-CAR-T set, the median TAFA-LEN treatment duration before CAR-T was 3.7 months with no patient becoming CD19 negative. The bORR, bCRR, 6- month PFS, and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1%, and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatment improved outcomes for patients relapsing after CAR T-cell therapy.

Blood AdvancesVol. 8(20)
Université Claude Bernard Lyon 1 (FR), Université de Tours (FR), Hôpital Necker-Enfants Malades (FR), Université de Bordeaux (FR), Inserm (FR), Université de Montpellier (FR), Université Paris Cité (FR), Centre Hospitalier Universitaire de Grenoble (FR), Institut Gustave Roussy (FR), Institut Pprime (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Nantes (FR), Université de Poitiers (FR), Sorbonne Université (FR), Centre Hospitalier Universitaire de Besançon (FR), Hôpital Cochin (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Hôpital Saint-Antoine (FR), The Lymphoma Academic Research Organisation (FR), Centre Hospitalier Universitaire d'Angers (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Établissement Français du Sang (FR), Hôpitaux Universitaires Henri-Mondor (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Hôpital Saint-Louis (FR), Institut Paoli-Calmettes (FR), Centre Virchow-Villermé (FR), Hôpital Claude Huriez (FR), Centre Hospitalier Universitaire de Rennes (FR), Hôpital Dupuytren (FR), Hôpital Albert Michallon (FR), Centre Henri Becquerel (FR), Microenvironment and B-cells: Immunopathology, Cell, Differentiation and Cancer (FR), Université d'Angers (FR), Université de Rennes (FR), Université de Strasbourg (FR), Institut Curie (FR), Nantes Université (FR), Université de Caen Normandie (FR)
Gilead Sciences, Incyte
Good health and well-being
Openalex Percentile: Top 6%
CAR-T cell therapy research
3.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.